Humana (NYSE:HUM – Get Free Report) was upgraded by stock analysts at Cantor Fitzgerald from a “neutral” rating to an “overweight” rating in a report issued on Wednesday, MarketBeat reports. The firm presently has a $460.00 price target on the insurance provider’s stock, up from their prior price target of $300.00. Cantor Fitzgerald’s target price would indicate a potential upside of 13.24% from the stock’s current price.
HUM has been the subject of several other research reports. Wolfe Research reissued an “outperform” rating and issued a $450.00 price objective on shares of Humana in a research note on Monday, August 24th. Morgan Stanley raised shares of Humana from an “underweight” rating to an “equal weight” rating and boosted their target price for the stock from $249.00 to $370.00 in a research note on Tuesday, August 4th. Robert W. Baird set a $390.00 price target on shares of Humana in a report on Thursday, July 30th. HSBC cut Humana to a “hold” rating in a research note on Thursday, July 30th. Finally, UBS Group assumed coverage on Humana in a research report on Thursday, July 30th. They set a “buy” rating on the stock. Sixteen analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Humana has a consensus rating of “Moderate Buy” and an average price target of $415.57.
Check Out Our Latest Report on Humana
Humana Stock Performance
Humana (NYSE:HUM – Get Free Report) last posted its earnings results on Wednesday, July 29th. The insurance provider reported $7.61 EPS for the quarter, topping analysts’ consensus estimates of $7.27 by $0.34. Humana had a net margin of 0.88% and a return on equity of 11.20%. The firm had revenue of $40.89 billion during the quarter, compared to analysts’ expectations of $40.58 billion. During the same quarter in the prior year, the business earned $6.27 earnings per share. The business’s revenue for the quarter was up 26.2% compared to the same quarter last year. As a group, analysts expect that Humana will post 9.01 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of HUM. Johnson Financial Group Inc. bought a new position in shares of Humana during the second quarter worth about $26,000. Trust Co. of Vermont bought a new stake in Humana in the second quarter valued at approximately $28,000. Bogart Wealth LLC increased its position in Humana by 192.0% during the 2nd quarter. Bogart Wealth LLC now owns 73 shares of the insurance provider’s stock valued at $29,000 after purchasing an additional 48 shares during the period. MidFirst Bank acquired a new stake in Humana during the 2nd quarter valued at approximately $35,000. Finally, Highland Investment Advisors LLC bought a new position in Humana during the 2nd quarter worth approximately $43,000. 92.38% of the stock is owned by institutional investors and hedge funds.
About Humana
Humana Inc is a health and well-being company headquartered in Louisville, Kentucky. Founded in 1961, the company began as a nursing home operator before expanding into hospitals and health insurance. Today, Humana primarily provides health insurance products and healthcare services for older adults, individuals, military families and other members in the United States.
Humana’s insurance business offers Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid coverage in select markets.
See Also
- Five stocks we like better than Humana
- Rivian Escapes the EV Graveyard—But Can It Stay Alive?
- Allient’s Data Center and Defense Momentum Is Raising the Stakes
- Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI
- Lamb Weston’s Turnaround Is Starting to Look Real
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.
